Ponke Thomas — investor profile photo

Ponke Thomas

--

📍 Greater Munich Metropolitan Area, Germany🔄 Updated November 2026💼 8 investments📅 14 years investing🗓 Last invested Dec 2022
Operator-angel🌍 Germany
8
Total investments
1
Early stage
3
Mid stage
1
Late stage
14y
Years active

Portfolio

6 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Shareholder
Dec 2022
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.
Shareholder
Feb 2022
We are building the next gen marketplace for Gen Z, enabling community-building and direct interaction via livestream shopping. Join VIOU and be part of a platform that will revolutionise e-commerce!
Shareholder
2021
Robotic solutions for sustainable farming. About the Robot --- Our robot is designed for mechanical weed removal, optimized for sugar beets and salads. It processes 3 rows in parallel and uses a 99% accurate AI-based optical system for weed/crop detection. With its lightweight aluminum body, operation on drying ground is possible way earlier than with heavy machines.
mid stageFarming
Shareholder
2014
Welcome to the state of brands We verleggen grenzen. We vinden uit. En we creëren. Wij zijn Blue Field Agency. Een marketingbureau in Amsterdam dat samen met een team van specialisten bouwt aan sterke merken. En uiteraard, allemaal gebaseerd op data. Zo weten we dat wàt we doen, ook echt is wat jouw merk nodig heeft. What’s your state of brand? Met inzicht van data bepalen we nauwkeurig de ‘staat’ van jouw merk. Deze data gebruiken we om met creativiteit, marketing en technologie jouw merk te laten groeien. Van slimme AI-analyses waardoor jij nieuwe leads kan aantrekken tot een brand awareness campagne voor meer naamsbekendheid. Let’s connect We maken alle aspecten van marketing totaal datagedreven. Onderzoek en een nauwkeurig gedefinieerde marketingstrategie zijn altijd ons vertrekpunt. We verbinden disciplines en weten precies welke combinatie een merk in beweging krijgt. Natuurlijk doen we dat samen met jou, omdat alleen de beste partnerships een merk in beweging krijgen.
Shareholder
2013
We are Sketchin: the advanced strategic-design studio that globally pioneers the future experience. We are based in Lugano, Milan, Rome and San Francisco. Born in Switzerland in 2006, we are today one of the biggest and fastest-growing design studios in Europe. We empower forward-thinking organizations to explore technology and face the future. We launch new endeavors and enhance human experiences. We shape business growth to create long-lasting value with a positive impact on people, communities and environment. Since September 2016 we are part of Bip Group. Why working with us? Because we evolve design! We experiment, explore and discover new experience opportunities. We want to push design further. Because we face big design challenges! Because we want a world where people live experiences that overcome their expectations and we use design to make it happen. Because we are a wonderful team! We are a smart, passionate and young group of people, we live in a place that resembles our attitudes and we live great experience together. Want to join us? hello@sketchin.com
late stageDesign Services
Founder and Shareholder
Jun 2012
At NBE Therapeutics we strive to develop best-in-class oncology treatments to increase survival and improve quality of life for cancer patients worldwide. Through our highly innovative novel in-house developed technologies, we have created a next generation antibody drug conjugate platform targeting solid tumors. Our platform allows us to develop targeted medicines, that through a long-lasting immune oncology effect, could reduce or even eradicate tumors. Our dedicated international team has been able to create a pipeline of ADC product candidates in various stages of development to enter clinical phases to create better treatments for cancer patients in need of more selective drugs.
Experience · 11 entries
All (11)
Investments (6)
Founder (5)
2024
Founder
Jul 2024
Leiden Sie unter trockener, juckender oder gestresster Haut? Herkömmliche Pflegeprodukte bringen oft nicht die gewünschte Linderung und enthalten zudem synthetische Inhaltsstoffe, die Ihre Haut zusätzlich belasten können. Bei OL2SKIN® kombinieren wir das Beste aus Natur und Wissenschaft. Unsere innovative Creme nutzt die Ortholamellare Technologie (OLT®), die der natürlichen Hautstruktur nachempfunden ist. Hochwertige, natürliche Inhaltsstoffe wie Bio-Olivenöl, Kurkuma und Honig der schwarzen Ur-Biene wirken entzündungshemmend und regenerieren die Mikroflora Ihrer Haut. Durch die Anwendung unserer Creme wird Ihre Haut beruhigt, die natürliche Barriere gestärkt und das Wohlbefinden spürbar verbessert. Sie erleben eine entspannte, gesunde Haut, die in Balance ist. Geben Sie Ihrer Haut die Pflege, die sie verdient. Besuchen Sie unsere Website und entdecken Sie die Kraft der natürlichen Hautpflege mit OL2SKIN®.
2022
Shareholder
Dec 2022
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.
Shareholder
Feb 2022
We are building the next gen marketplace for Gen Z, enabling community-building and direct interaction via livestream shopping. Join VIOU and be part of a platform that will revolutionise e-commerce!
2021
Shareholder
2021
Robotic solutions for sustainable farming. About the Robot --- Our robot is designed for mechanical weed removal, optimized for sugar beets and salads. It processes 3 rows in parallel and uses a 99% accurate AI-based optical system for weed/crop detection. With its lightweight aluminum body, operation on drying ground is possible way earlier than with heavy machines.
mid stageFarming
2015
Maremma Sapori di S.P.
Owner
2015
Show all 11 entries ↓
Investment activity
2012–2022 · 8 investments
2012120132201422021120222
Recent (last 2 years)Earlier
Investor lists
Lists that match Ponke's portfolio